# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $7 pr...
RBC Capital analyst Brian Abrahams reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and maintains $3 price...
Baird analyst Mitch Collett maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price target fr...
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate ...
HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price...
HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 pr...
- SEC Filing